« Previous Next » Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 703-709 , May 2011

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation

Filippo Milano
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
- Department of Cellular Biotechnologies and Haematology, University “La Sapienza,” Rome, Italy
- Correspondence and reprint requests: Filippo Milano, 1100 Fairview Avenue North, Mailstop D2-100, Seattle, WA 98109-1024.
Margaret A. Au
- Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington
- Department of Epidemiology, Cancer Research Center, University of Hawaii, Honolulu, Hawaii
Michael J. Boeckh
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
- Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington
H. Joachim Deeg
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
- Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington
Jason W. Chien
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
- Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington

Received 30 June 2010 ,Accepted 14 August 2010.

Annualized rate of FEV₁ decline during 2 time intervals (pretransplantation to 1 year posttransplantation) for the ATG and non-ATG groups. The rate of FEV₁ decline is categorized as <5%, 5%-15%, or >2

Annualized rate of FEV₁ decline during 2 time intervals (pretransplantation to 1 year posttransplantation) for the ATG and non-ATG groups. The rate of FEV₁ decline is categorized as <5%, 5%-15%, or >20% per year. P = .409, pretransplantation to 1 year posttransplantation.
- Full-Size Image
- Download to PowerPoint